Proof of concept of AAV gene therapy for MPS IIIA was initially reported in neonatal MPS IIIA mice after ICV injections of an AAV5 vector carrying both human SGSH and sulfatase modifying factor 1 (SUMF1) transgenes.117. Here, SGSH is linked to mucopolysaccharidosis type 3A.